Phase III, randomised, double-blind, placebo-controlled, multicentre trial to evaluate the efficacy and safety of rhGAD65 to preserve endogenous beta cell function in adolescents and adults with recently diagnosed type 1 diabetes, carrying the genetic HLA DR3-DQ2 haplotype: the DIAGNODE-3 study protocol

INTRODUCTION: Type 1 diabetes (T1D) is an autoimmune disease leading to the destruction of the insulin-producing beta cells resulting in insulin deficiency and hyperglycaemic. Today, no approved therapy exists to halt this detrimental immunologic process. In a recent phase 2b study, intralymphatic a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ludvigsson, Johnny, Eriksson, Linnea, Nowak, Christoph, Teixeira, Pedro F, Widman, Martina, Lindqvist, Anton, Casas, Rosaura, Lind, Marcus, Hannelius, Ulf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Diabetes and Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628549/
https://www.ncbi.nlm.nih.gov/pubmed/36316084
http://dx.doi.org/10.1136/bmjopen-2022-061776

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628549/
https://www.ncbi.nlm.nih.gov/pubmed/36316084
http://dx.doi.org/10.1136/bmjopen-2022-061776

Ejemplares similares